AstraZeneca | 6-K: Ultomiris Approved in the Us for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder
AstraZeneca | DFAN14A: Definitive additional proxy soliciting materials filed by non-management
AstraZeneca | F-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
AstraZeneca | 6-K: Astrazeneca to Acquire Fusion to Accelerate the Development of Next-Generation Radioconjugates to Treat Cancer
AstraZeneca | 6-K: AstraZeneca to Acquire Amolyt
AstraZeneca | 6-K: Transaction by Person Discharging Managerial Responsibilities
AstraZeneca | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
AstraZeneca | 6-K: Notice of Annual General Meeting
AstraZeneca | 6-K: Astrazeneca Plc Announced That, On 5 March 2024, An Award of the Company's Ordinary Shares of $0.25 Each Vested to Pascal Soriot, Executive Director and Chief Executive Officer, Under the Terms of the Astrazeneca Deferred Bonus Plan
AstraZeneca | 6-K: Transactions by Persons Discharging Managerial Responsibilities
AstraZeneca | CERT: Others
AstraZeneca | 8-A12B: Registration of a class of securities on a national securities exchange
AstraZeneca | 6-K: EMA validates Dato-DXd MAAs for NSQ NSCLC and BC
AstraZeneca | 6-K: Voting Rights and Capital
AstraZeneca | 6-K: Closure of Notes Sale Pursuant to Underwriting Agreement
AstraZeneca | 6-K: Voydeya Recommended for Approval in the Eu by CHMP as Add-On Treatment to Ravulizumab or Eculizumab for Adults with PNH Who Have Residual Haemolytic Anaemia
AstraZeneca | 424B2: Prospectus
AstraZeneca | FWP: Filing under Securities Act Rules 163/433 of free writing prospectuses
AstraZeneca | 6-K: Astrazeneca Prices a $5bn Bond Offering
AstraZeneca | 6-K: Acquisition of Gracell Completed
No Data